Klinik Dr. Hancken GmbH
- Address
- Harsefelder Str. 8, 21680 Stade, Germany
Klinik Dr. Hancken GmbH - Oncology Research Center
Klinik Dr. Hancken GmbH is a specialized oncology research center with extensive expertise in conducting multi-phase clinical trials across a diverse range of cancer types. The center demonstrates particular strength in investigating novel therapeutic approaches, including antibody-drug conjugates, targeted therapies, and personalized treatment strategies that leverage biomarker-guided decision-making.
- Breast Cancer Research: Leading trials in HER2-positive and triple-negative breast cancer, including neoadjuvant and adjuvant therapy optimization with agents like sacituzumab govitecan, trastuzumab-deruxtecan, and ribociclib
- Gastrointestinal Oncology: Advanced investigations in colon cancer (preoperative systemic therapy, ctDNA-guided adjuvant treatment) and esophagogastric adenocarcinoma
- Hematologic Malignancies: Phase III trials in advanced-stage Hodgkin lymphoma comparing toxicity-reduced regimens with standard escalated chemotherapy
- Digital Health Integration: Pioneering research evaluating digital patient monitoring solutions and at-home treatment administration in lung cancer and hepatocellular carcinoma
The center's research portfolio emphasizes precision oncology through dynamic marker-adjusted personalized therapy (ADAPT) trials and circulating tumor DNA (ctDNA) monitoring. With participation in innovative platform studies exploring both novel therapeutics and digital health solutions, Klinik Dr. Hancken GmbH contributes significantly to advancing treatment paradigms that balance efficacy with reduced toxicity and improved patient quality of life across multiple cancer indications.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 therapeutic areas and 15 of 32 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Klinik Dr. Hancken GmbH
lock Showing 1 of 11 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized Study of Sacituzumab Govitecan and Pembrolizumab Versus Physician's Choice in Triple Negative Breast Cancer with Residual Invasive Disease | Gilead Sciences Inc. | Phase III | Recruiting | Nov 2024 | — |
IMP list
lock Showing 1 of 32 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Capecitabine | 4 | Unknown | 2019-12-04 | 2025-04-01 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.